Skip to main content

Advertisement

SpringerLink
Log in

Impact of chronic kidney disease on in-hospital mortality and clinical outcomes of catheter ablation of ventricular tachycardia: Insights from the national readmission database

  • Published:
Journal of Interventional Cardiac Electrophysiology Aims and scope Submit manuscript

A Correction to this article was published on 03 April 2023

This article has been updated

Abstract

Background

Catheter ablation is an effective treatment for ventricular tachycardia (VT), albeit the decision to undergo this procedure is often influenced by underlying comorbidities. The present study aims at evaluating the effects of chronic kidney disease (CKD) on clinical outcomes of VT ablation.

Methods

We identified 7212 patients who presented between 2016 and 2018 and underwent catheter ablation for VT. Their clinical data were retrospectively accrued from the national readmission database (NRD) using the corresponding diagnosis codes. We compared clinical outcomes between patients with chronic kidney disease (CKD group) and patients without. Odds ratios (OR) for the primary and secondary outcomes were calculated, and multivariable regression analysis was utilized to adjust for confounding variables.

Results

Compared with patients without CKD, patients in CKD group were older (mean age 67.9 vs. 60.5 years, P < 0.01), had a longer mean length of stay (8.73 vs. 5.69 days, P < 0.01), and higher in-hospital mortality 113 (6.7%) vs. 119 (2.2%) (OR 2.24, 95% confidence interval (CI) (1.29–3.88), P < 0.01). CKD group patients had increased risk of developing acute kidney injury 726 (43%) vs. 623 (11.3%) (3.69 95% CI (2.87–4.74), P < 0.01).

Conclusion

In patients with CKD, VT ablation is associated with worse clinical outcomes in-hospital mortality, acute kidney injury, mean length of stay, and total hospital charge. This significantly influences the decision-making prior to performing this procedure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Change history

References

  1. Kuriachan VP, Sumner GL, Mitchell LB. Sudden cardiac death. Curr Probl Cardiol. 2015;40(4):133–200.

    Article  PubMed  Google Scholar 

  2. de Bakker JM, van Capelle FJ, Janse MJ, Tasseron S, Vermeulen JT, de Jonge N, et al. Slow conduction in the infarcted human heart. ‘Zigzag’ course of activation. Circulation. 1993;88(3):915–26.

  3. Reddy VY, Reynolds MR, Neuzil P, Richardson AW, Taborsky M, Jongnarangsin K, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med. 2007;357(26):2657–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Sapp JL, Wells GA, Parkash R, Stevenson WG, Blier L, Sarrazin JF, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med. 2016;375(2):111–21.

    Article  CAS  PubMed  Google Scholar 

  5. Gunda S, Padala SK, Saini A, Kang L, Ellenbogen KA, Koneru JN. Risk score model for predicting complications in patients undergoing ventricular tachycardia ablation: insights from the National Inpatient Sample database. Europace. 2019;21(3):475–83.

    Article  PubMed  Google Scholar 

  6. Bloom JE, Dinh DT, Noaman S, Martin C, Lim M, Batchelor R, et al. Adverse impact of chronic kidney disease on clinical outcomes following percutaneous coronary intervention. Catheter Cardiovasc Interv. 2021;97(6):E801–9.

    Article  PubMed  Google Scholar 

  7. Sharma P, Tripathi B, Naraparaju V, Patel M, Bhagat A, Yerasi C, et al. Short-term outcomes associated with inpatient ventricular tachycardia catheter ablation. Pacing Clin Electrophysiol. 2020;43(5):444–55.

    Article  PubMed  Google Scholar 

  8. Palaniswamy C, Kolte D, Harikrishnan P, Khera S, Aronow WS, Mujib M, et al. Catheter ablation of postinfarction ventricular tachycardia: ten-year trends in utilization, in-hospital complications, and in-hospital mortality in the United States. Heart Rhythm. 2014;11(11):2056–63.

    Article  PubMed  Google Scholar 

  9. Campbell T, Bennett RG, Kotake Y, Kumar S. Updates in ventricular tachycardia ablation. Kor Circ J. 2021;51(1):15–42.

    Article  CAS  Google Scholar 

  10. Cronin EM, Bogun FM, Maury P, Peichl P, Chen M, Namboodiri N, et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Europace. 2019;21(8):1143–4.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Pothineni NV, Deshmukh A, Padmanabhan D, Kovelamudi S, Patel NJ, Badheka AO, et al. Complication rates of ventricular tachycardia ablation: comparison of safety outcomes derived from administrative databases and clinical trials. Int J Cardiol. 2015;201:529–31.

    Article  PubMed  Google Scholar 

  12. Maini R, Wong DB, Addison D, Chiang E, Weisbord SD, Jneid H. Persistent underrepresentation of kidney disease in randomized, controlled trials of cardiovascular disease in the contemporary era. J Am Soc Nephrol. 2018;29(12):2782–6.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Cheung JW, Yeo I, Ip JE, Thomas G, Liu CF, Markowitz SM, et al. Outcomes, costs, and 30-day readmissions after catheter ablation of myocardial infarct-associated ventricular tachycardia in the real world: nationwide readmissions database 2010 to 2015. Circ Arrhythm Electrophysiol. 2018;11(11):e006754.

    Article  PubMed  Google Scholar 

  14. Calkins H, Bigger JT Jr, Ackerman SJ, Duff SB, Wilber D, Kerr RA, et al. Cost-effectiveness of catheter ablation in patients with ventricular tachycardia. Circulation. 2000;101(3):280–8.

    Article  CAS  PubMed  Google Scholar 

  15. Stompór T. Coronary artery calcification in chronic kidney disease: an update. World J Cardiol. 2014;6(4):115–29.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Liu P, Wang L, Han D, Sun C, Xue X, Li G. Acquired long QT syndrome in chronic kidney disease patients. Ren Fail. 2020;42(1):54–65.

    Article  PubMed  Google Scholar 

  17. Bonato FOB, Canziani MEF. Ventricular arrhythmia in chronic kidney disease patients. J Bras Nefrol. 2017;39(2):186–95.

    Article  PubMed  Google Scholar 

  18. Karmin O, Siow YL. Metabolic imbalance of homocysteine and hydrogen sulfide in kidney disease. Curr Med Chem. 2018;25(3):367–77.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Internal Medicine Department Lincoln Medical and Mental Health Center, NY, New York, USA

    Mahmoud Khalil

  2. Cardiovascular Medicine Department, Tanta University, Tanta, Egypt

    Mahmoud Khalil

  3. Department of Internal Medicine, CHI St. Alexius Health/University of North Dakota, Bismarck, ND, USA

    Ahmed Maraey

  4. Department of Internal Medicine, Lahey Hospital and Medical Center, Burlington, MA, USA

    Amro Aglan

  5. Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

    Amro Aglan

  6. Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA

    Emmanuel Akintoye

  7. Center for Advanced Heart and Lung Diseases, Baylor University Medical Center, TX, Dallas, USA

    Mahmoud Salem

  8. Cardiovascular Medicine Department, University of Toledo, Toledo, OH, USA

    Ahmed M. Elzanaty

  9. Internal Medicine Department, East Carolina University, Greenville, NC, USA

    Ahmed Younes

  10. Internal Medicine Department, Saint Mary Hospital, Waterbury, CT, USA

    Ayman Saeyeldin

  11. Leon H. Charney Division of Cardiology, Cardiac Electrophysiology, NYU Langone Health, New York University School of Medicine, New York City, NY, USA

    Chirag R. Barbhaiya & Mohamed Shokr

Authors
  1. Mahmoud Khalil
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ahmed Maraey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amro Aglan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emmanuel Akintoye
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mahmoud Salem
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ahmed M. Elzanaty
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ahmed Younes
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ayman Saeyeldin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chirag R. Barbhaiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mohamed Shokr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mahmoud Khalil.

Ethics declarations

Ethical approval

This study doesn’t need review by the institutional review board because of the de-identified nature of the data in the NRD.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised: The author name Chirag R. Barbhaiya was incorrectly written as Chirag R. Barbhaiaya.

Electronic Supplementary Material

ESM 1

(DOCX 17.2 kb)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Khalil, M., Maraey, A., Aglan, A. et al. Impact of chronic kidney disease on in-hospital mortality and clinical outcomes of catheter ablation of ventricular tachycardia: Insights from the national readmission database. J Interv Card Electrophysiol 66, 323–331 (2023). https://doi.org/10.1007/s10840-022-01187-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10840-022-01187-z

Keywords

Search

Navigation